Baidu
map

Int Arch Allergy Immunol:鼻腔内给药IL-27能够减轻鼻过敏性响应和症状

2018-12-17 AlexYang MedSci原创

白介素(IL-27)是Th1响应的一个抑制子,并能够抑制炎症响应。在一个哮喘小鼠模型中,IL-27给药能够减少气管肺泡灌洗和气道高反应中的嗜酸性粒细胞数目。然而,是否IL-27给药能够抑制过敏性疾病和过敏性鼻炎的症状仍旧不清楚。因此,有研究人员调查了体内IL-27给药对鼻症状和过敏性鼻炎的影响。研究人员在利用OVA敏感和诱导的小鼠中进行IL-27鼻腔给药试验。研究发现,与对照PBS鼻腔给药相比,鼻

白介素(IL-27)是Th1响应的一个抑制子,并能够抑制炎症响应。在一个哮喘小鼠模型中,IL-27给药能够减少气管肺泡灌洗和气道高反应中的嗜酸性粒细胞数目。然而,是否IL-27给药能够抑制过敏性疾病和过敏性鼻炎的症状仍旧不清楚。因此,有研究人员调查了体内IL-27给药对鼻症状和过敏性鼻炎的影响。

研究人员在利用OVA敏感和诱导的小鼠中进行IL-27鼻腔给药试验。研究发现,与对照PBS鼻腔给药相比,鼻腔内给药IL-27能够显著的抑制打喷嚏和摩擦鼻子的次数、嗜酸性粒细胞数、颈部淋巴结中OVA特异性T细胞响应、IL-4和IL-5的产生和血清中特异性lgE。另外,IL-10和IL-35的产生、CD25+Foxp3+细胞的比例和Foxp3的基因表达在IL-27处理的小鼠中比那些只接受PBS处理的小鼠显著更高。

最后,研究人员指出,他们首次证明了鼻腔内IL-27给药能够抑制鼻过敏性响应和症状,甚至是在过敏性鼻炎中也有类似的效果,表明了IL-27可能是一个有用的鼻腔治疗药物。

原始出处:

Suzuki M, Yokota M, Ozaki S et al. Intranasal Administration of IL-27 Ameliorates Nasal Allergic Responses and Symptoms. Int Arch Allergy Immunol. Nov 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047053, encodeId=9020204e053a6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 05 22:08:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329185, encodeId=47f0132918594, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465843, encodeId=30371465843ec, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626039, encodeId=1a541626039fa, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047053, encodeId=9020204e053a6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 05 22:08:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329185, encodeId=47f0132918594, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465843, encodeId=30371465843ec, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626039, encodeId=1a541626039fa, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2018-12-19 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047053, encodeId=9020204e053a6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 05 22:08:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329185, encodeId=47f0132918594, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465843, encodeId=30371465843ec, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626039, encodeId=1a541626039fa, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2018-12-19 mnda
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047053, encodeId=9020204e053a6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun May 05 22:08:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329185, encodeId=47f0132918594, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465843, encodeId=30371465843ec, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626039, encodeId=1a541626039fa, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Wed Dec 19 14:08:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2018-12-19 tomyang93

相关资讯

Allergy Asthma Clin Immunol:中国北方一个乡村地区过敏性和非过敏性鼻炎流行度分析

大多数流行病学研究报道过敏性鼻炎(AR)和非过敏性鼻炎(NAR)时只评估了自我报道的流行度,并没有进行客观的测量确定。更多的是,关于中国人口的NAR流行度报道非常少见。因此,最近有研究人员探索了中国人口中AR和NAR的流行度和风险因子,且主要基于临床表现和过敏状态。研究人员进行的是一个基于群体的代表性调查,包括了中国北京的1084名当地居民。研究发现,自我报道的AR流行度为46.8%。基于SPT结

Toxicol Lett:PM2.5接触能够增加恶化过敏性鼻炎

过敏性鼻炎(AR)是一种常见的慢性炎症疾病,并且对患者的生活质量具有明显的影响。之前的研究表明了PM2.5能够通过表观遗传调控影响儿科AR,但是潜在的机制仍旧不清楚。最近,有研究人员创制了一个小鼠模型,并在PM2.5处理后评估了鼻部症状、病理变化、INF-γ基因启动子的甲基化水平和ERK-DNMT途径的激活情况。研究结果表明,PM2.5能够导致更加严重的AR症状。另外,PM2.5接触在AR组中能够

J Laryngol Otol:永久性和间歇性过敏性鼻炎患者中,鼻涂片嗜酸性粒细胞分析

嗜酸性粒细胞是过敏性鼻炎致病机制的首要响应细胞。在非过敏性的鼻炎、过敏性鼻炎、嗜酸性粒细胞过多、阿司匹林过敏和鼻息肉中的细胞数据患者中,细胞的数目均增多。脱落鼻细胞学可以用来对过敏性鼻炎进行不同的诊断。最近,有研究人员评估了具有轻度、永久和间歇性过敏性鼻炎患者的鼻涂片中评估嗜酸性粒细胞。研究包括了60名患有过敏性鼻炎的患者和20名健康志愿者。患者分成间歇性和永久过敏性鼻炎2个小组,并且比较了鼻涂片

Allergol Immunopathol (Madr):过敏性鼻炎中,B细胞OX40配体与CD4+ T细胞血清总lgE和IL-4水平相关性分析

过敏性鼻炎(AR)是一种经典的Th2调节的疾病,能够引起重要的白介素4、5和13的病理性变化。OX40共刺激分子和它的配体互作参与了Th1/Th2细胞平衡调控的免疫响应。考虑到OX40配体(OX40L)与AR之间相关信息的缺乏,最近,有研究人员调查了OX40配体在B淋巴细胞中的表达。研究包括了20名AR患者和20名健康参与者。研究人员利用电化学发光免疫检测(ECL)技术对总血清lgE水平进行测量,

Eur Arch Otorhinolaryngol: 过敏性鼻炎对鼻粘膜重建的不同影响研究

过敏性鼻炎(AR)已经报道与慢性鼻窦炎(CRS)相关。最近,有研究人员调查了AR对CRS鼻粘膜重建的影响。研究人员将募集的患者分成不同的小组:具有鼻息肉(NP)和过敏性鼻炎(AR)的CRS患者(CRSwNPwAR,n=20)、具有NP,不具有AR的CRS患者(CRSwNPsAR; n?=?20)、不具有NP,具有AR的CRS患者(CRSsNPwAR; n?=?20)、不具有NP和AR的CRS患者(

Int Arch Allergy Immunol:在过敏性鼻炎中,MiR-202-5p能够促进M2极化

最近,有研究人员调查了MiR-202-5p对过敏性鼻炎中巨噬细胞的影响。研究包括了30名过敏性鼻炎的患者和10名健康的对照。研究人员利用鼻腔灌洗来收集鼻组织和来源于粘液的巨噬细胞,并利用流式细胞仪检测和分选了2型巨噬细胞,并且还利用qRT-PCR和蛋白免疫印迹来确定MiR-202-5p和MATN2的表达情况。研究人员还利用荧光素酶和生物素RNA-pulldown试验测试了miR-202-5p与MA

Baidu
map
Baidu
map
Baidu
map